Rollover Study of BMS-354825 in Patients With CML and Ph+ALL
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
To assess the safety of dasatinib (BMS-354825) in subjects with Imatinib resistant or
intolerant chronic myelogenous leukemia (CML) and Philadelphia chromosome positive (Ph+)
acute lymphoblastic leukemia (ALL) who are resistant or intolerant to treatment and will
continue study drug after completing the previous Phase I/II study (CA180031/NCT00337454)